alemtuzumab (Campath)

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical and Pharmacy Editor: Jay W. Marks, MD
    Jay W. Marks, MD

    Jay W. Marks, MD

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

Take the Leukemia Quiz


Possible serious side effects include:

PREPARATIONS: Injection (single use vial): 30 mg/vial

DRUG INTERACTIONS: Alemtuzumab drug interaction studies have not been conducted.


  • Proteins such as alemtuzumab, may cross the placental barrier and may be excreted in breast milk. Alemtuzumab has not been studied in pregnant women or nursing mothers. It should be given to a pregnant or nursing woman only if clearly needed.

STORAGE: Alemtuzumab should be stored at 2 C to 8 C (36 F to 46 F), protected from light, and not frozen. If frozen, thaw to 2 to 8 C before administration.

Medically Reviewed by a Doctor on 6/15/2016
Leukemia Quiz: Test Your Medical IQ
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Cancer Report Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors